CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
C4 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.89+0.13 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-320.5%
Net margin
-292.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.0% | +5.0% | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -78.6% | -44.4% | |
| Return on assets | – | -25.6% | -29.6% | |
| Current ratio | – | 8.69 | 7.81 | |
| Debt to equity | – | 0.04 | – | |
| Net debt to EBITDA | – | 2.96× | – | |
| Capex to revenue | – | – | 1.7% | |
| Diluted shares | – | 11M | 83M |
Where the cash went
Fiscal 2021 to 2025, five years combined
C4 Therapeutics generated $463.59M from operations and spent $9.77M on capital expenditure, dividends and share buybacks. 95% of that went back into the business.
Generated
$463.59M
Used
$9.77M
Capital expenditure$9.27M95%Dividends$00%Share buybacks$497.00K5%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-292.1%
×Asset turnover0.10×
×Equity multiplier1.50×
=Return on equity, FY2025-44.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -292.1% | 0.10× | 1.50× | -44.4% |
| FY2024 | -296.0% | 0.10× | 1.57× | -45.6% |
| FY2023 | -638.3% | 0.05× | 1.51× | -49.5% |
| FY2022 | -412.2% | 0.07× | 1.38× | -37.8% |
| FY2021 | -183.2% | 0.10× | 1.35× | -25.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$104.99M
- Cash generatingOperating cash flow above zero-$98.69M
- Return on assets improvedROA up on the prior year-28.0% → -30.0%
- Earnings backed by cashOperating cash flow above net income-$98.69M vs -$104.99M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.71 → 7.81
- No dilutionShare count did not rise69M → 83M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.09 → 0.10